Back to Authors

Khurshid, Humera

0009-0008-1758-6411

Mayo Clinic

Brown University

Citations 2

Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights
Khurshid, Humera , Ismaila, Nofisat , Das, Millie , Manochakian, Rami , Weinberg, Frank , Kalemkerian, Gregory P. , Manochakian, Rami , Weinberg, Frank , Kalemkerian, Gregory P , Das, Millie , Kulkarni, Swati

JCO Oncology Practice | November 20, 2024 | Volume: 21 | Issue: 6 | Pages: 754-758

10.1200/op-24-00840 Get It

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline
Khurshid, Humera , Ismaila, Nofisat , Bian, Jessica , Dabney, Raetasha, Das, Millie , Ellis, Peter , Hann, Christine L. , Laskin, Janessa , Mishra, Deebya Raj , Reddy, Pavan S. , Saxena, Ashish , Kalemkerian, Gregory P. , Hann, Christine , Laskin, Janessa , Manochakian, Rami , Mishra, Deebya Raj , Preeshagul, Isabel , Reddy, Pavan , Weinberg, Frank , Kalemkerian, Gregory P , Das, Millie , Feldman, Jill , Kulkarni, Swati , Manochakian, Rami , Weinberg, Frank

Journal of Clinical Oncology | October 11, 2023 | Volume: 41 | Issue: 35 | Pages: 5448-5472

10.1200/jco.23.01435 Get It

PURPOSE To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer. METHODS An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 95 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer. Additional information is available at www.asco.org/thoracic-cancer-guidelines .